China's Price Cuts And Antibiotic Limits Weigh On Simcere, But Merck JV Opens Doors
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Nanjing, China's Simcere Pharmaceutical Group reported a slowdown in sales for the second quarter, pointing to intense competition from the spread of Anhui province's tender model for essential drugs and price cuts on products included in the National Drug Reimbursement List
You may also be interested in...
Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs
Merck/Simcere, Pfizer/Hisun launched JVs in China this week to increase sales in outlying cities.
Dance With Domestic Companies: Pfizer And Merck Look To Broaden Market Access In China Via JVs
Merck/Simcere, Pfizer/Hisun launched JVs in China this week to increase sales in outlying cities.
Merck And Simcere Trial Partnership In China: Two Different Cultures But One Common Goal
NANJING, China - A few weeks after Merck & Co.'s China affiliate MSD and one of China's leading drug makers Simcere Pharmaceutical Group announced a new joint venture to expand access to critical lifestyle drugs across China, the two companies unveiled more details to their innovative partnership